目的 探討乙肝舒康膠囊聯(lián)合恩替卡韋和復(fù)方甘草酸苷治療慢性重癥乙型肝炎的臨床療效。方法 選取2015年1月-2016年1月在延安大學(xué)附屬醫(yī)院接受治療的慢性重癥乙型肝炎患者96例，按照治療方法的差別分成對照組和治療組，每組各48例。對照組口服恩替卡韋片，1片/次，1次/d；并口服復(fù)方甘草酸苷片，3片/次，3次/d。治療組在對照組基礎(chǔ)上口服乙肝舒康膠囊，4粒/次，3次/d。兩組患者均治療16周。觀察兩組的臨床療效，比較兩組的肝功能和乙肝病毒脫氧核糖核酸（HBV-DNA）水平。結(jié)果 治療后，對照組和治療組的總有效率分別為83.33%、95.83%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組丙氨酸轉(zhuǎn)氨酶（ALT）、天氨酸轉(zhuǎn)氨酶（AST）、總膽紅素（TBIL）及直接膽紅素（DBIL）均明顯降低，而凝血酶原活動度（PTA）顯著升高，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組這些觀察指標(biāo)的改善程度明顯優(yōu)于對照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組HBV-DNA水平均明顯降低，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組HBV-DNA水平的下降程度明顯優(yōu)于對照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 乙肝舒康膠囊聯(lián)合恩替卡韋和復(fù)方甘草酸苷治療慢性重癥乙型肝炎具有較好的療效，可明顯降低患者血清HBV-DNA水平，改善患者肝功能，具有一定的臨床推廣應(yīng)用價值。

Objective To investigate the clinical effect of Yigan Shukang Capsules combined with entecavir and compound glycyrrhizin in treatment of chronic severe hepatitis B. Methods Patients (86 cases) with chronic severe hepatitis B in Yan'an University Affiliated Hospital from January 2015 to January 2016 were enrolled in this study. According to the difference treatment plan, patients were divided into control and treatment groups, and each group had 48 cases. Patients in the control group were po administered with Entecavir Tablets, 1 tablet/time, once daily. And patients in the control group were also po administered with Compound Glycyrrhizin Tablets, 3 tablet/time, three times daily Patients in the treatment group were po administered with Yigan Shukang Capsules on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 16 weeks. After treatment, the clinical efficacies were evaluated, and liver function and HBV-DNA levels in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 83.33% and 95.83%, respectively, and there was difference between two groups (P<0.05). After treatment, ALT, AST, TBIL, and DBIL in two groups were significantly decreased, but PTA in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, the HBV-DNA levels in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the HBV-DNA level in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). Conclusion Yigan Shukang Capsules combined with entecavir and compound glycyrrhizin has clinical curative effect in treatment of chronic severe hepatitis B, and can significantly decrease serum HBV-DNA level, improve liver function, which has a certain clinical application value.